Using them may promote mild weight loss results
Common triggers include anxiety, dehydration, caffeine, or other medications, so its helpful to consider these factors alongside semaglutide use
While it doesn't directly predict sweating, it reveals your genetic thermoregulatory and metabolic profile, helping your provider anticipate your response and personalize your therapy from the start
Semaglutide leads the risk profile With a reporting odds ratio of 2.46 in the FAERS database, semaglutide carries the highest documented risk of alopecia among GLP-1 receptor agonists
Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
Muscle loss acceptable: Patient prioritizes scale weight over body composition ratio
